BioSpace News Archive

Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) (“Defence” or the “Company”), a leading Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the discovery of a novel function for its lead anticancer injectable drug AccuTOX® in the context of cell-based cancer vaccine engineering.

PENTAX Medical America Inc., a division of HOYA Group, has launched two of its latest innovations: the PENTAX Medical INSPIRA™, a premier 4K video processor, and the i20c video endoscope series.

Orthopaedic Solutions Management, a physician-led orthopedic focused management services organization, is proud to announce its expansion into two new Florida markets, Gainesville and Ocala.

~ The Rymedi platform, with unrivaled security, is transforming healthcare data exchange for laboratories, occupational health, healthcare systems, and clinical trials ~

Vesigen Therapeutics, Inc. today presented data highlighting the potential of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) technology to overcome fundamental delivery challenges that limit the clinical application of emerging treatment modalities.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 1, 2023.

Regeneron Pharmaceuticals, Inc. will webcast management participation as follows.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 8:30 a.m. ET on Friday, November 3, 2023 to report its third quarter financial results and provide a business update.

Lipella Pharmaceuticals Inc. announced the closing of its previously announced private placement transaction, priced at-the-market under Nasdaq rules, for the purchase and sale of pre-funded warrants to purchase up to an aggregate of 1,315,790 shares and warrants to purchase up to an aggregate of 1,315,790 shares.

Medicenna Therapeutics Corp. today announced dosing of the first patient in the Phase 2 monotherapy dose expansion portion of the Phase 1/2 ABILITY (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting, beta-only interleukin-2 (IL-2) super-agonist.